Literature DB >> 3921286

Evidence for the biclonal nature of a Waldenstrom's macroglobulinemia.

L Bonewald, G Virella, A C Wang.   

Abstract

The serum of a patient with Waldenstrom's macroglobulinemia was shown to contain two IgM(kappa) paraproteins of different electrophoretic mobilities on cellulose acetate and immunoelectrophoresis and were designated IgM slow (s) and IgM fast (f). Both existed as high molecular weight polymers and contained a J chain. The two pentameric IgM monoclonal proteins were shown to be completely distinct in carbohydrate composition as determined by gas chromatography and periodic acid-Schiff staining, in molecular weight, by physicochemical properties, peptide mapping, amino-acid composition, NH2-terminal sequence, subgroup of light chains, and by lack of shared idiotypic determinants as determined by hemagglutination inhibition studies. Our study presents strong evidence for the 'bioclonal' nature of this gammopathy. We conclude that both paraproteins are distinct and originated from different B cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3921286     DOI: 10.1016/0009-8981(85)90123-8

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  2 in total

1.  IgG-associated immune thrombocytopenia in Waldenström macroglobulinemia.

Authors:  Kumi Nakazaki; Akira Hangaishi; Fumihiko Nakamura; Masataka Hosoi; Yoichi Imai; Tsuyoshi Takahashi; Yasuhito Nannya; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2010-07-24       Impact factor: 2.490

2.  Lymphoplasmacytic lymphoma associated with diffuse large B-cell lymphoma: Progression or divergent evolution?

Authors:  Macarena Boiza-Sánchez; Rebeca Manso; Olga Balagué; Cristina Chamizo; Elham Askari; Rocío Nieves Salgado; Carlos Blas-López; Elena Aguirregoicoa-García; Javier Menárguez; Carlos Santonja; Magdalena Adrados; Miguel Ángel Limeres-González; Miguel Ángel Piris; Socorro María Rodríguez-Pinilla
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.